Gokarn Karuna, Pal Ramprasad B
Department of Microbiology, Sir Hurkisondas Nurrotumdas Medical Research Society, Mumbai, 400 002, India.
Caius Research Laboratory, St. Xavier's College, Mumbai, 400 001, India.
BMC Complement Altern Med. 2017 Mar 21;17(1):161. doi: 10.1186/s12906-017-1665-8.
Alternative treatment strategies have become essential in overcoming the problem of drug-resistant Mycobacterium tuberculosis (Mtb). In this preliminary in vitro study, the anti-tuberculosis (anti-TB) activity of exogenous iron chelators (xenosiderophores) such as Exochelin-MS (Exo-MS) and Deferoxamine-B (DFO-B) was evaluated against ten multi-drug-resistant (MDR) and seven pyrazinamide-resistant (PZA ) Mtb isolates.
Mycobacteria Growth Indicator Tube-Drug Susceptibility Test was used to assess the anti-TB effect of Exo-MS or DFO-B individually and their combinations with isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA).
For the MDR-Mtb isolates, Exo-MS alone inhibited two out of the five isolates tested. Whereas, DFO-B alone inhibited nine out of the ten MDR isolates tested. For PZA-resistant Mtb isolates, both Exo-MS and DFO-B individually inhibited five out of the seven isolates. The MIC of Exo-MS in combination with INH, RIF and PZA remained the same. The MIC of DFO-B decreased when tested in combination with INH, RIF and PZA.
Exo-MS and DFO-B were shown to have activity against drug-resistant Mtb isolates. Therefore, these xenosiderophores may be useful adjuncts to antibiotics in overcoming the problem of drug-resistant Mtb in clinical setting.
替代治疗策略对于克服耐多药结核分枝杆菌(Mtb)问题已变得至关重要。在这项初步的体外研究中,评估了外源性铁螯合剂(异源铁载体)如Exochelin-MS(Exo-MS)和去铁胺-B(DFO-B)对10株耐多药(MDR)和7株耐吡嗪酰胺(PZA)结核分枝杆菌分离株的抗结核活性。
采用分枝杆菌生长指示管药敏试验分别评估Exo-MS或DFO-B及其与异烟肼(INH)、利福平(RIF)和吡嗪酰胺(PZA)联合使用的抗结核效果。
对于耐多药结核分枝杆菌分离株,单独使用Exo-MS抑制了所测试的5株分离株中的2株。而单独使用DFO-B抑制了所测试的10株耐多药分离株中的9株。对于耐吡嗪酰胺结核分枝杆菌分离株,Exo-MS和DFO-B单独使用时均抑制了7株分离株中的5株。Exo-MS与INH、RIF和PZA联合使用时的最低抑菌浓度(MIC)保持不变。DFO-B与INH、RIF和PZA联合测试时MIC降低。
Exo-MS和DFO-B显示出对耐多药结核分枝杆菌分离株有活性。因此,这些异源铁载体在临床环境中克服耐多药结核分枝杆菌问题时可能是抗生素的有用辅助药物。